BioVaxys Technology Corp.

ETOBICOKE, A6 · Founded 2018 · CIK 0001882559 · Biotech · Public

Haptenized protein vaccines and DPX™ delivery technology for antiviral and cancer immunotherapy

biovaxys.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$301K
2 Form D · Jul 2024
27 months since last filing
Contracts
—
No federal contracts on record
Patents
1
0 granted · 1 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$248,540
Private capital raisedForm D · SEC$52,324
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1187Ikena Oncology—$43M
1188SHIP OF THESEUS, LLC——
1189Bridge Therapeutics, Inc.—$321K
1190BioVaxys Technology Corp.—$301K
1191Petri Bio LLC—$255K
1192PreveCeutical Medical Inc.—$254K
1193KELIOMICS, INC.—$250K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 9 related persons
  • David BerdExecutive Officer
  • Christopher CherryExecutive Officer
  • Anthony DuttonDirector
  • Daren HermistonDirector
  • Kenneth KovanExecutive Officer
  • Craig LoverockDirector
  • Lachlan McLeodExecutive Officer
  • James PassinDirector · Executive Officer
  • David WangDirector

Patents

USPTO · 0 granted of 1
  • Vaccine Compositions Comprising A Neoantigen Of Krasapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.